The government on Wednesday after reviewing the supply and demand situation of Remdesivir with manufacturers and other stakeholders, decided to fast track approvals to raise production by 10 lakh vials per month.
Manufacturers of Remdesivir have also volunteered to reduce the price to less than Rs 3,500 per vial by the end of this week, to support the efforts of the government in the fight against COVID-19 second wave.
The current total installed capacity of the seven manufacturers of Remdesivir is 38.80 lakh vials per month.
Fast-track approval has been given for seven additional sites having the production capacity of 10 Lakh vials /month to six manufacturers.
Seven manufactures Cipla, Hetero, Dr Reddy's, Zydus Cadila, Jubilant, Mylan and Syngene have licenses from US drug maker Gilead to manufacture and export the drug in 127 low and middle income countries.
Another 30 lakh vials/month production is lined up. This would ramp up the production capacity for manufacturing to around 78 lakh vials/month.
As an additional measure, Remdesivir, API and formulation were placed under Export ban on April 11 by the government to increase the supply of Remdesivir in the domestic market.
"On Government intervention, Remdesivir supplies of approximately 4 lakh vials meant for export is being diverted by manufacturers to fulfil domestic requirement," the government said in a release.
Manufactures of Remdesivir have been directed to give priority to fulfil hospital level supplies.
The Export Oriented Units are also being enabled to supply to the domestic market.
Mansukh Mandaviya, Minister of State, For Ports, Shipping and Waterways (Independent Charge) and Chemicals& Fertilizers, Government of India in met all-existing manufacturers of the Remdesivir drug and other stakeholders on 12th and 13th April 2021, where decisions have been taken to increase production/supply and reduce prices of Remdesivir.
Enforcement Authorities of States and Central government have been directed by the Drug Controller General of India (DCGI) to take immediate action on incidence of black-marketing, hoarding and overcharging of Remdesivir.
National Pharmaceutical Pricing Authority (NPPA) is continuously monitoring the availability of Remdesivir.
Remdesivir used in the hospitalised COVID-19 patients, who need 5-6 injections.